Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel.
复制标题
DOI：
10.1056/nejmoa2114255
复制
发表时间：
2021-10-07
期刊：
影响因子：
--
通讯作者：
Huppert A
中科院分区：
文献类型：
--
作者：
Bar-On YM;Goldberg Y;Mandel M;Bodenheimer O;Freedman L;Kalkstein N;Mizrahi B;Alroy-Preis S;Ash N;Milo R;Huppert A
2021年7月30日，以色列批准为60岁或以上且至少5个月前接种过第二剂疫苗的人接种第三剂（加强）BNT 162 b2信使RNA疫苗（辉瑞BioNTech）。需要关于加强剂量对确诊的2019冠状病毒病（Covid-19）发病率和重症发病率的影响的数据。我们从以色列卫生部数据库中提取了2021年7月30日至8月31日期间的数据，涉及1，137，804名60岁或以上的人，他们已经完全接种疫苗（即，至少5个月前接受了两剂BNT 162 b2）。在初步分析中，我们比较了至少12天前接受过加强注射的人（加强组）和没有接受过加强注射的人（非加强组）的确诊率和重症率。在二次分析中，我们评估了加强剂量后4至6天的感染率，并与加强剂量后至少12天的感染率进行了比较。在所有分析中，我们在调整可能的混杂因素后使用Poisson回归。在加强剂量后至少12天，加强组的确诊感染率比非加强组低11.3倍（95%置信区间[CI]，10.4 - 12.3）;严重疾病率低19.5倍（95% CI，12.9 - 29.5）。在二次分析中，疫苗接种后至少12天的确诊感染率比4 - 6天后的确诊感染率低5.4倍（95% CI，4.8 - 6.1）。在这项涉及60岁或60岁以上且至少在5个月前接种了两剂BNT 162 b2疫苗的参与者的研究中，我们发现，在接种了加强剂（第三剂）BNT 162 b2疫苗的参与者中，确诊的Covid-19和严重疾病的发生率显著降低。
On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least 5 months earlier. Data are needed regarding the effect of the booster dose on the rate of confirmed coronavirus 2019 disease (Covid-19) and the rate of severe illness. We extracted data for the period from July 30 through August 31, 2021, from the Israeli Ministry of Health database regarding 1,137,804 persons who were 60 years of age or older and had been fully vaccinated (i.e., had received two doses of BNT162b2) at least 5 months earlier. In the primary analysis, we compared the rate of confirmed Covid-19 and the rate of severe illness between those who had received a booster injection at least 12 days earlier (booster group) and those who had not received a booster injection (nonbooster group). In a secondary analysis, we evaluated the rate of infection 4 to 6 days after the booster dose as compared with the rate at least 12 days after the booster. In all the analyses, we used Poisson regression after adjusting for possible confounding factors. At least 12 days after the booster dose, the rate of confirmed infection was lower in the booster group than in the nonbooster group by a factor of 11.3 (95% confidence interval [CI], 10.4 to 12.3); the rate of severe illness was lower by a factor of 19.5 (95% CI, 12.9 to 29.5). In a secondary analysis, the rate of confirmed infection at least 12 days after vaccination was lower than the rate after 4 to 6 days by a factor of 5.4 (95% CI, 4.8 to 6.1). In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine.